Accession Number: | 0001223203-19-000038 |
Date: | 2019-05-08 |
Issuer: | EDWARDS LIFESCIENCES CORP (EW) |
Original Submission Date: |
MUSSALLEM MICHAEL A
C/O EDWARDS LIFESCIENCES CORP
ONE EDWARDS WAY
IRVINE, CA 92614
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2019-05-08 | A | 8,675 | a | $0.00 | 51,801 | direct | ||
COMMON STOCK | 2019-05-08 | 0 | $0.00 | 123,925 | indirect | f2 | |||
COMMON STOCK | 2019-05-08 | 0 | $0.00 | 745,400 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO ACQUIRE) | 177.77 | 2019-05-08 | deemed execution date | A | 85,600 (a) | 2019-06-08 | 2026-05-07 | common stock 85,600 | $177.77 | 85,600 | direct | |
PERFORMANCE RIGHTS | 0.0 | 2019-05-08 | deemed execution date | A | 10,825 (a) | 2022-05-08 | 2026-05-07 | common stock 10,825 | $0.00 | 10,825 | direct |
ID | footnote |
---|---|
f1 | these restricted stock units were granted on may 8, 2019 under the edwards lifesciences corporation long-term stock incentive compensation program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. |
f2 | shares represented on the most recent statement of issuer's 401(k) plan administrator. |
f3 | these options were granted on may 8, 2019 under the edwards lifesciences corporation long-term stock incentive compensation program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. |
f4 | reflects the target number of shares (the target award) covered by restricted stock units granted under the edwards lifesciences corporation long-term stock incentive compensation program on may 8, 2019 and scheduled to vest on may 8, 2022. the number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the target awards. |